Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Unaudited Preliminary Results Announcement)
Reporting Period: Year ended 31 December 2008 and Quarter ended 31 December 2008
Issuance Date: 5 February 2009
GSK reported a "turning point" year in 2008, characterized by a radical transformation of its business model to reduce risk and deliver sustainable growth. Performance was impacted by significant US patent expiries, declines in Avandia sales, and an unexpected legal charge in Q4. The company announced an expansion of its restructuring programme to simplify operations and support strategic priorities.
Key Financial Metrics
| Metric | 2008 Full Year (£m) | 2008 Q4 (£m) | 2007 Full Year (£m) |
|---|---|---|---|
| Turnover | 24,352 | 6,910 | 22,716 |
| Operating Profit (Before Restructuring) | 8,259 | 2,106 | 7,931 |
| Operating Profit (Total) | 7,141 | 1,582 | 7,593 |
| Profit After Tax (Attributable to Shareholders) | 4,602 | 982 | 5,214 |
| Earnings Per Share (Before Restructuring) | 104.7p | 26.7p | 99.1p |
| Earnings Per Share (Total) | 88.6p | 19.3p | 94.4p |
| Net Cash Inflow from Operating Activities | 7,311 | N/A | 6,161 |
| Net Debt (Year End) | 10,173 | N/A | 6,039 |
Margins (2008 vs 2007):
- Cost of Sales: 23.7% (vs 22.9%)
- SG&A (excluding legal): 27.7% (vs 28.9%)
- R&D: 14.4% (vs 14.3%)
- Effective Tax Rate: 29.2% (vs 28.7%)
Material Changes vs. Prior Period
- Revenue: Total turnover declined 3% in Constant Exchange Rate (CER) terms but rose 7% in sterling terms due to currency movements. Pharmaceuticals turnover fell 3% (CER), while Consumer Healthcare rose 3% (CER).
- Profitability: EPS before major restructuring fell 9% in CER terms (up 6% in sterling). Total EPS fell 21% in CER terms (down 6% in sterling).
- Restructuring Charges: Major restructuring charges increased significantly to £1,118 million for the full year (2007: £338 million), driven by the expansion of the Operational Excellence programme.
- Legal Charges: A £278 million charge was recorded in Q4 related to a US investigation into marketing practices (Colorado). Total legal costs for the year were £611 million (2007: £255 million).
- Product Performance:
- Declines: Avandia sales fell 40% to £805 million; Lamictal fell 22% due to US generic competition; Relenza fell 80% due to fewer government orders.
- Growth: Vaccines sales rose 15% to £2.5 billion (driven by Cervarix and Rotarix); Advair sales rose 8% to £4.1 billion; Emerging Markets sales grew 12%.
- Balance Sheet: Net debt increased by £4.1 billion to £10.2 billion, primarily due to share buybacks (£3.7 billion) and dividend payments. Pension deficit widened to £1.7 billion due to actuarial losses.
Guidance, Outlook, and Risks
- Guidance Change: GSK announced it will no longer provide specific short-term numerical earnings guidance, focusing instead on long-term strategic priorities.
- Restructuring Outlook: The expanded restructuring programme targets pre-tax annual savings of £1.7 billion by 2011, with total charges of £3.6 billion. Savings are expected to mitigate expected gross margin declines in 2009.
- 2009 Expectations: Management expects cost of sales to be 24-25% of turnover and SG&A (excluding legal) to be slightly higher than 2008 due to increased marketing investment. Currency weakness is expected to provide a positive impact of around 25 percentage points on 2009 sterling EPS growth.
- Risks and Contingencies:
- Legal: Ongoing investigations and litigation regarding marketing practices and patent infringement (e.g., Seretide, Combivir). Aggregate provision for legal disputes is £1.9 billion.
- Patent Expiries: Continued impact of generic competition on mature brands in the US.
- Pension: Significant actuarial losses increased the pension deficit, impacting net assets.
Key Facts for Investor Verification
- EPS Quality: Verify the sustainability of earnings excluding the £278 million legal charge and the impact of the expanded £3.6 billion restructuring programme on future cash flows.
- Avandia Trajectory: Monitor the stabilization of Avandia sales, which declined 40% in 2008, and the impact of regulatory actions on future revenue.
- Restructuring Execution: Track the realization of the targeted £1.7 billion in annual savings by 2011 and the associated job reduction impacts.
- Debt Profile: Assess the increase in net debt to £10.2 billion and the company's ability to service this debt while maintaining dividend growth (increased 8% to 57p).
- Pipeline Progress: Verify the regulatory status of key late-stage assets (e.g., pazopanib, Syncria, ofatumumab) which are critical for future growth.